Circulating Myeloid-derived Suppressor Cells Predict Disease Activity and Treatment Response in Patients with Immune Thrombocytopenia

Overview

Journal Braz J Med Biol Res

Specialties Biology
General Medicine

Date 2017 Feb 23

PMID 28225866

Citations 6

Authors

J Zhou

Y Zhou

J Wen

X Sun

X Zhang

Affiliations

Soon will be listed here.

Abstract

Immune thrombocytopenia (ITP) is a disease characterized by isolated thrombocytopenia. Abnormal effector T cell activation is an important mechanism in the pathogenesis of ITP. Regulatory T cells (Treg) have a strong immunosuppressive function for T cell activation and their importance in the pathophysiology and clinical treatment of ITP has been confirmed. Myeloid-derived suppressor cells (MDSCs) are other immunosuppressive cells, which can also suppress T cell activation by secreting arginase, iNOS and ROS, and are essential for Treg cells' differentiation and maturation. Therefore, we speculate that MDSCs might also be involved in the immune-dysregulation mechanism of ITP. In this study, we tested MDSCs and Treg cells in peripheral blood samples of twenty-five ITP patients and ten healthy donors. We found that MDSCs and Treg cells decreased simultaneously in active ITP patients. Relapsed ITP patients showed lower MDSCs levels compared with new patients. All patients received immunosuppressive treatment including dexamethasone alone or in combination with intravenous immune globulin. We found that MDSCs' level after treatment correlated with platelet recovery. Our study is the first that focused on MDSCs' role in ITP. Based on our results, we concluded that circulating MDSCs could predict disease activity and treatment response in ITP patients. This preliminary conclusion indicates a substantial significance of MDSCs in the pathophysiology and clinical treatment of ITP, which deserves further investigation.

Citing Articles

Thrombopoietin receptor agonists regulate myeloid-derived suppressor cell-mediated immunomodulatory effects in ITP.

Zhu Y, Wang Y, Zhao Y, Liu D, Wang X, Zhu L Ann Hematol. 2024; 103(8):2729-2741.

PMID: 38890176 DOI: 10.1007/s00277-024-05846-1.

Study on the mechanism of MDSC-platelets and their role in the breast cancer microenvironment.

Han X, Song X, Xiao Z, Zhu G, Gao R, Ni B Front Cell Dev Biol. 2024; 12:1310442.

PMID: 38404689 PMC: 10884319. DOI: 10.3389/fcell.2024.1310442.

New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology.

Bizymi N, Matthaiou A, Matheakakis A, Voulgari I, Aresti N, Zavitsanou K J Clin Med. 2022; 11(18).

PMID: 36142973 PMC: 9504532. DOI: 10.3390/jcm11185326.

Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondrial metabolism in immune thrombocytopenia.

Hou Y, Xie J, Wang S, Li D, Wang L, Wang H Cell Mol Immunol. 2022; 19(7):764-776.

PMID: 35414712 PMC: 9243139. DOI: 10.1038/s41423-022-00859-0.

Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets.

Bizymi N, Bjelica S, Olsnes Kittang A, Mojsilovic S, Velegraki M, Pontikoglou C Hemasphere. 2019; 3(1):e168.

PMID: 31723807 PMC: 6745940. DOI: 10.1097/HS9.0000000000000168.

References

Gantt S, Gervassi A, Jaspan H, Horton H . The role of myeloid-derived suppressor cells in immune ontogeny. Front Immunol. 2014; 5:387. PMC: 4131407. DOI: 10.3389/fimmu.2014.00387. View

Serafini P . Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly. Immunol Res. 2013; 57(1-3):172-84. DOI: 10.1007/s12026-013-8455-2. View

Rodeghiero F, Ruggeri M . ITP and international guidelines: what do we know, what do we need?. Presse Med. 2014; 43(4 Pt 2):e61-7. DOI: 10.1016/j.lpm.2014.02.004. View

Nishimoto T, Satoh T, Takeuchi T, Ikeda Y, Kuwana M . Critical role of CD4(+)CD25(+) regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Exp Hematol. 2012; 40(4):279-89. DOI: 10.1016/j.exphem.2012.01.001. View

Lo E, Deane S . Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev. 2014; 13(4-5):577-83. DOI: 10.1016/j.autrev.2014.01.026. View

Marvel D, Gabrilovich D . Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125(9):3356-64. PMC: 4588239. DOI: 10.1172/JCI80005. View

Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V . Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014; 1319:47-65. DOI: 10.1111/nyas.12469. View

Nishimoto T, Kuwana M . CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol. 2013; 50 Suppl 1:S43-9. DOI: 10.1053/j.seminhematol.2013.03.018. View

Toltl L, Arnold D . Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters. Br J Haematol. 2010; 152(1):52-60. PMC: 4854616. DOI: 10.1111/j.1365-2141.2010.08412.x. View

10.

Huang B, Pan P, Li Q, Sato A, Levy D, Bromberg J . Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006; 66(2):1123-31. DOI: 10.1158/0008-5472.CAN-05-1299. View

11.

Cretney E, Kallies A, Nutt S . Differentiation and function of Foxp3(+) effector regulatory T cells. Trends Immunol. 2012; 34(2):74-80. DOI: 10.1016/j.it.2012.11.002. View

12.

Liu B, Zhao H, Poon M, Han Z, Gu D, Xu M . Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol. 2007; 78(2):139-43. DOI: 10.1111/j.1600-0609.2006.00780.x. View

13.

Brimnes M, Vangsted A, Knudsen L, Gimsing P, Gang A, Johnsen H . Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010; 72(6):540-7. DOI: 10.1111/j.1365-3083.2010.02463.x. View

14.

Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel J . Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008; 112(4):1325-8. PMC: 2515134. DOI: 10.1182/blood-2008-01-135335. View

15.

Ling Y, Cao X, Yu Z, Ruan C . Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol. 2007; 79(4):310-6. DOI: 10.1111/j.1600-0609.2007.00917.x. View

16.

Kashiwagi H, Tomiyama Y . Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013; 98(1):24-33. DOI: 10.1007/s12185-013-1370-4. View

17.

Dilek N, Poirier N, Usal C, Martinet B, Blancho G, Vanhove B . Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J Immunol. 2012; 188(9):4209-16. DOI: 10.4049/jimmunol.1101512. View

18.

Sakakura M, Wada H, Tawara I, Nobori T, Sugiyama T, Sagawa N . Reduced Cd4+Cd25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2006; 120(2):187-93. DOI: 10.1016/j.thromres.2006.09.008. View

19.

Serafini P, Mgebroff S, Noonan K, Borrello I . Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008; 68(13):5439-49. PMC: 2887390. DOI: 10.1158/0008-5472.CAN-07-6621. View

20.

Zahran A, Elsayh K . CD4+ CD25+High Foxp3+ regulatory T cells, B lymphocytes, and T lymphocytes in patients with acute ITP in Assiut Children Hospital. Clin Appl Thromb Hemost. 2012; 20(1):61-7. DOI: 10.1177/1076029612454937. View